Entity Details

Primary name CHRNB1
Entity type gene
Source Source Link

Details

PrimaryID1140
RefseqGeneNG_008026
SymbolCHRNB1
Namecholinergic receptor nicotinic beta 1 subunit
Chromosome17
Location17p13.1
TaxID9606
Statuslive
SourceGenomegenomic
SourceOriginnatural
CreationDate1990-05-11
ModificationDate2021-06-11

Ontological Relatives

UniProt IDsACHB_HUMAN

GO terms

Show/Hide Table
GOName
GO:0001941 postsynaptic membrane organization
GO:0003009 skeletal muscle contraction
GO:0004888 transmembrane signaling receptor activity
GO:0005887 integral component of plasma membrane
GO:0005892 acetylcholine-gated channel complex
GO:0006812 cation transport
GO:0006936 muscle contraction
GO:0007165 signal transduction
GO:0007268 chemical synaptic transmission
GO:0007271 synaptic transmission, cholinergic
GO:0007274 neuromuscular synaptic transmission
GO:0015267 channel activity
GO:0015276 ligand-gated ion channel activity
GO:0022848 acetylcholine-gated cation-selective channel activity
GO:0030594 neurotransmitter receptor activity
GO:0031594 neuromuscular junction
GO:0034220 ion transmembrane transport
GO:0035095 behavioral response to nicotine
GO:0042166 acetylcholine binding
GO:0042391 regulation of membrane potential
GO:0043005 neuron projection
GO:0045202 synapse
GO:0050877 nervous system process
GO:0099060 integral component of postsynaptic specialization membrane
GO:1904315 transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential

Diseases

Show/Hide Table
Disease IDSourceNameDescription
616313 OMIMMyasthenic syndrome, congenital, 2A, slow-channel (CMS2A)A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS2A is a slow-channel myasthenic syndrome. It is caused by kinetic abnormalities of the AChR, resulting in prolonged AChR channel opening episodes, prolonged endplate currents, and depolarization block. This is associated with calcium overload, which may contribute to subsequent degeneration of the endplate and postsynaptic membrane. The disease is caused by variants affecting the gene represented in this entry.
616314 OMIMMyasthenic syndrome, congenital, 2C, associated with acetylcholine receptor deficiency (CMS2C)A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS2C is an autosomal recessive disorder of postsynaptic neuromuscular transmission, due to deficiency of AChR at the endplate that results in low amplitude of the miniature endplate potential and current. CMS2C is clinically characterized by early-onset muscle weakness with variable severity. The disease is caused by variants affecting the gene represented in this entry.

Interactions

3 interactions

InteractorPartnerSourcesPublicationsLink
CHRNB1COPS6HPRD, IntAct16169070 details
CHRNB1ASB6BioGRID, IntAct32296183 details
CHRNB1RAPSNHPRD16280586 details